Daily News

Hospital CEO apologises for not using public tender process, but says the hospital needed to ‘balance the need for public procurement with the need to respond immediately to urgent demand’

Irish Medical Times

St James’s pays €4.7 million to company run by its own consultants for scans without public tendering process ↗

?

Inspection found overall positive responses in doctors’ training experiences, but under-resourced systems led to delays and welfare concerns

Irish Medical Times

HR and IT systems in CHI hospitals pose risk to patient safety – Medical Council ↗

?

Agreement with pharmaceutical sector a ‘critical step’ in ensuring faster patient access to new treatments, says industry body

Irish Medical Times

Government commits to meeting six-month deadline for drug reimbursement under new deal ↗

?

Global body calls on governments to significantly strengthen taxes on sugary drinks and alcoholic beverages, but commends Ireland’s minimum unit pricing policy

Irish Medical Times

Sugary and alcoholic drinks getting cheaper, fuelling rise in diseases – WHO ↗

?

Pictured at the official ‘topping out’ of the new RCSI Dental Education Centre at Connolly Hospital, Blanchardstown was Minister Minister for Public

Irish Medical Times

New RCSI Dental Education Centre ‘topped out’ ↗

?

Over 2,000 more over-75s presented to Limerick ED last year compared to 2024

Irish Medical Times

UHL sees 17 per cent rise in admissions of over-75s from ED ↗

?

Common human papillomavirus infection can lead to cervical, throat, anal, penile and vulval cancers

Irish Medical Times

HPV vaccine catch-up programme extended to older second-level students ↗

?

PADCEV (enfortumab vedotin) plus Keytruda (pembrolizumab) is the first and only regimen without platinum-based chemotherapy to improve event-free and overall survival when used before and after surgery in cisplatin-eligible patients with muscle-invasive bladder cancer

Irish Medical Times

PADCEV▼ (enfortumab vedotin) Plus Keytruda Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility ↗

?

8⬆️